Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says

Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says

Upworthy

Published

None Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. • None JMP has raised the price target from $182 to $312 and reiterates its Market Outperform rating. • None Resmetirom looks approvable based…

#pfe #lly #gileadsciencesinc #merckcoinc #pfizerinc #nonejmp #elilillyandco #novartisag #mrk #astrazenecaplc

Full Article